Avadel Pharmaceuticals (AVDL)

• Market cap: $986M
• 1 day: 0.89%
• 5 days: -4.39%
• 1 month: -8.82%
• 3 months: -19.95%
• 6 months: -29.79%
• Year to date: -28.36%
• 1 year: -26.93%
• 5 years: 46.56%
• 10 years: -39.86%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.

Employees: 154

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

88% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 25

27% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 44

14% more funds holding

Funds holding: 153 [Q2] → 175 (+22) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 8 [Q2] → 8 (+0) [Q3]

0.25% less ownership

Funds ownership: 77.59% [Q2] → 77.33% (-0.25%) [Q3]

27% less call options, than puts

Call options by funds: $35.8M | Put options by funds: $48.9M

29% less capital invested

Capital invested by funds: $1.37B [Q2] → $976M (-$393M) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $22 115% upside
• Avg. target: $26 151% upside
• High target: $30 193% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Oren Livnat 50% 1-year accuracy 23 / 46 met price target	144% upside $25	Buy Maintained	13 Nov 2024
Needham Ami Fadia 32% 1-year accuracy 49 / 154 met price target	115% upside $22	Buy Reiterated	13 Nov 2024
Oppenheimer Francois Brisebois 43% 1-year accuracy 15 / 35 met price target	193% upside $30	Outperform Maintained	31 Oct 2024